Pioneering Precision Mind Award Unveils Groundbreaking Biomarker Research to Transform Psychiatric Care in Franco-British Collaboration

On April 13, 2026, in London, a landmark event in mental health research unfolded as Wakam, the National Institute for Health and Care Research (NIHR) Mental Health Translational Research Collaboration, and the Fondation FondaMental proudly announced the laureates of the inaugural Precision Mind Award. Launched in November 2025 as a cornerstone of the ambitious Franco-British consortium dedicated to psychiatric biomarker research, this prestigious award champions collaborative projects between the two nations focused on the crucial identification and validation of biomarkers for mental illnesses. The selection process, rigorously conducted by an independent scientific committee, underscored the commitment to scientific excellence and impartiality in advancing this critical field. This announcement marks a pivotal moment in the global effort to revolutionize the diagnosis and treatment of mental health conditions, moving towards an era of precision psychiatry that promises to alleviate suffering for millions worldwide.

The Global Imperative for Precision Psychiatry

The urgency underpinning initiatives like the Precision Mind Award is stark and undeniable. According to the World Health Organization (WHO), over one billion people globally are affected by a mental illness, a staggering figure that underscores the pervasive nature of these conditions. Disorders such as depression, bipolar disorder, and schizophrenia are not merely personal struggles but represent a monumental public health challenge, consistently ranking among the leading causes of disability worldwide. The human toll is immense, with these pathologies often reducing life expectancy by 10 to 20 years, far exceeding the impact of many chronic physical ailments. Beyond the individual suffering, the societal and economic burden is profound, encompassing lost productivity, increased healthcare costs, and significant strain on social support systems.

Despite the widespread prevalence and devastating impact of mental illnesses, the field of psychiatry has historically lagged behind other medical disciplines in the development of objective diagnostic tools. Unlike cardiology, oncology, or infectious diseases, where quantifiable biomarkers—such as blood markers, digital signatures, or imaging data—are routinely used to precisely identify diseases, guide treatment, and monitor progression, psychiatric diagnoses largely rely on subjective symptom reporting and clinical observation. This critical absence of objective biomarkers leads to several significant challenges: diagnoses are often delayed, treatments are frequently arrived at through a trial-and-error process, and personalized medicine, a standard in many other areas of healthcare, remains largely elusive in mental health. Patients endure prolonged periods of distress, ineffective therapies, and the profound frustration of a healthcare system struggling to provide truly tailored care. The promise of biomarkers is to usher in a new era where mental health conditions can be identified earlier, more accurately, and managed with treatments specifically designed for an individual’s unique biological profile.

A Collaborative Vision: The Genesis of the Precision Mind Award

Recognizing this urgent need for transformation, the visionary partnership between Wakam, a pioneering insurtech company, and the Fondation FondaMental, a leading French foundation dedicated to mental health research, laid the groundwork for the Precision Mind Award. This alliance was soon fortified by the invaluable expertise of the National Institute for Health and Care Research (NIHR) Mental Health Translational Research Collaboration, a formidable network dedicated to accelerating the translation of research findings into clinical practice. Together, these entities forged the Franco-British consortium, a powerful transatlantic collaboration aimed at bridging the research gap in psychiatric biomarkers.

The inspiration for this initiative drew directly from the remarkable success seen in the field of neurodegenerative diseases. The Dementia Discovery Fund, for instance, a similar collaborative consortium, played a pivotal role in the identification of crucial blood markers for Alzheimer’s and Parkinson’s diseases. These breakthroughs have fundamentally reshaped the diagnostic landscape and opened new avenues for therapeutic development in neurology. The consortium firmly believes that psychiatry can, and indeed must, achieve similar successes, harnessing the power of collaborative, interdisciplinary research to unlock the biological underpinnings of mental illness. The Precision Mind Award was conceived as a catalyst for this transformation, providing vital funding and recognition to projects at the forefront of this scientific endeavor.

Timeline of a Transatlantic Endeavor

The journey towards the Precision Mind Award laureates unfolded with strategic precision:

• Pre-November 2025: The Franco-British consortium for psychiatric biomarker research is formally established, bringing together key institutions and funding bodies from both nations. Discussions and planning for a dedicated award program commence.
• November 2025: The Precision Mind Award is officially launched. Calls for proposals are disseminated across leading research institutions in France and the United Kingdom, inviting collaborative teams to submit their innovative biomarker research projects. The criteria emphasize novelty, scientific rigor, and the potential for clinical impact.
• November 2025 – Early 2026: A rigorous submission and review process takes place. Research teams from across France and the UK, comprising diverse expertise in neuroscience, immunology, genetics, and clinical psychiatry, prepare and submit their detailed project proposals.
• Early 2026: An independent scientific committee, composed of distinguished experts in psychiatry and biomarker research from various international institutions, meticulously evaluates the submitted projects. This committee is tasked with assessing scientific merit, collaborative potential, feasibility, and the potential for real-world application.
• April 13, 2026: The highly anticipated announcement of the inaugural Precision Mind Award laureates is made in London, marking a significant milestone for the consortium and the wider mental health research community. The chosen projects represent the cutting edge of biomarker discovery.
• Post-April 2026: The awarded projects receive their respective funding allocations from Wakam and the NIHR. Research teams embark on the next phases of their studies, with regular reporting and scientific exchange facilitated by the consortium, ensuring accelerated progress and collaborative synergy.

Pioneering Research Projects: A Glimpse into the Future of Mental Health

The two projects selected for the inaugural Precision Mind Award exemplify the innovative and collaborative spirit central to the consortium’s mission. Each addresses a critical, unmet need in mental health, promising to illuminate the biological mechanisms underlying complex psychiatric symptoms.

Laureate N°1 – Wakam Endowment: AUTOSCREEN – When the Immune System Attacks the Brain: Detecting Autoimmune Psychoses

• Project Leaders: Dr. Adam Al-Diwani (University of Oxford, United Kingdom) & Dr. Laurent Groc (CNRS / University of Bordeaux, France)
• The Challenge: Certain forms of psychosis manifest abruptly, presenting with atypical symptoms that often prove resistant to conventional treatments. This subset of patients represents a significant diagnostic and therapeutic conundrum, leading to prolonged suffering and poor outcomes.
• The Hypothesis: The AUTOSCREEN project explores a compelling and increasingly recognized hypothesis: that these recalcitrant psychoses might be triggered by a dysregulation of the immune system. In these cases, the body’s immune system mistakenly produces auto-antibodies that target and attack brain cells, disrupting normal brain function and leading to the emergence of autoimmune psychoses. This understanding offers a fundamentally different paradigm for understanding and treating these conditions.
• The Collaborative Approach:
  • In the United Kingdom: Dr. Al-Diwani’s team at the University of Oxford will leverage cutting-edge cellular models. They will cultivate human neurons derived from stem cells in laboratory settings, allowing for direct observation of whether antibodies present in the blood of affected patients attack brain cells. This direct in vitro model provides a powerful platform to confirm the pathogenic role of specific auto-antibodies.
  • In Bordeaux, France: Dr. Groc’s team at the CNRS / University of Bordeaux will employ "super-resolved" microscopy techniques. This advanced imaging technology allows for the detection and study of auto-antibodies at the nanoscale, offering unprecedented resolution into the intricate biological mechanisms at play. This detailed molecular insight is crucial for understanding how these auto-antibodies interact with neuronal targets and disrupt brain function.
• The Ultimate Goal: The overarching objective of AUTOSCREEN is to identify distinct biological signatures characteristic of patients whose psychosis has an immune origin. Such identification would pave the way for a paradigm shift in treatment, enabling clinicians to offer targeted immunological therapies, such as immunomodulators, as a complement to traditional psychiatric medications. This personalized approach holds the potential to significantly improve treatment response and long-term outcomes for patients suffering from these challenging forms of psychosis.

Laureate N°2 – NIHR Mental Health Translational Research Collaboration Endowment: Immuno-Metabolic Profile of Anhedonia – Why Do Some Patients No Longer Feel Any Motivation or Pleasure?

• Project Leaders: Dr. Mireille Laforge (NeuroDiderot – INSERM, IHU-ICE Robert Debré – Paris, France) & Dr. Fabiana Corsi-Zuelli (University of Oxford / UKRI-MRC, United Kingdom)
• The Challenge: Anhedonia, defined as the profound loss of capacity to experience pleasure or motivation, is a particularly debilitating symptom common across a spectrum of psychiatric disorders, including depression, bipolar disorder, and psychotic disorders. It is often the most treatment-resistant symptom and profoundly degrades patients’ quality of life, making daily activities feel meaningless and stripping life of its joy.
• The Hypothesis: Recent research increasingly suggests that anhedonia might be linked to chronic, low-grade inflammation within the body. This subtle but persistent inflammatory state is thought to disrupt the metabolism of immune cells, potentially impacting neural circuits involved in reward and motivation. Understanding this intricate interplay between inflammation, metabolism, and brain function is key to developing new therapeutic strategies.
• The Collaborative Approach:
  • In the United Kingdom: Dr. Corsi-Zuelli’s team at the University of Oxford will conduct in-depth biological analyses on blood samples collected from patients. The goal is to identify specific molecular signatures associated with the severity of anhedonia, effectively creating a "biological fingerprint" for this symptom. These analyses will leverage advanced omics technologies (e.g., proteomics, metabolomics) to capture a comprehensive view of biological changes.
  • In Paris, France: Dr. Laforge’s team at NeuroDiderot will utilize state-of-the-art techniques to meticulously observe immune cells and measure their bioenergetic signature. This will allow researchers to understand precisely how these cells function differently in patients affected by anhedonia, shedding light on the metabolic pathways that are disrupted.
• The Originality of the Approach: A defining feature of this project is its "trans-diagnostic" focus. Instead of studying anhedonia within the confines of a single psychiatric diagnosis, the researchers are investigating it as a common symptom, irrespective of the underlying psychiatric illness. This approach recognizes that shared biological mechanisms might drive similar symptoms across different diagnostic categories.
• Collaborative Infrastructure: This project benefits significantly from collaboration with Dr. Livia Carvalho (Queen Mary, London) and is integrated into the UK Mental Health Platform (MHP). The MHP is a national infrastructure funded by UKRI/MRC, designed to enable harmonized biological and clinical research in mental health, providing invaluable resources and standardized protocols. The funding for this Precision Mind Award endowment is directly provided by the NIHR, channeled through the NIHR Mental Health Translational Research Collaboration (MH-TRC), underscoring the NIHR’s commitment to this area of research.
• The Ultimate Goal: In the long term, the insights gained from this project could lead to the development of novel treatments specifically targeting anhedonia, potentially through anti-inflammatory or metabolic interventions, which would complement existing therapeutic strategies. This would offer new hope for millions of patients currently struggling with this debilitating symptom.

Statements and Reactions: A Unified Vision for the Future

The unveiling of the Precision Mind Award laureates was met with widespread enthusiasm and optimism from all collaborating partners.

A representative from Wakam stated, "Our commitment at Wakam extends beyond traditional insurance. We believe in leveraging innovation to solve pressing societal challenges, and mental health is undoubtedly one of the most critical. Sponsoring the AUTOSCREEN project through the Precision Mind Award is an investment in a future where severe psychoses can be accurately diagnosed and effectively treated, fundamentally changing lives for the better. This Franco-British collaboration is a testament to what can be achieved when diverse expertise unites for a common, noble cause."

A spokesperson for the NIHR Mental Health Translational Research Collaboration emphasized, "The NIHR is dedicated to transforming mental health research into tangible patient benefits. The Immuno-Metabolic Profile of Anhedonia project, funded by our collaboration, exemplifies the kind of translational research we champion. By focusing on a debilitating symptom like anhedonia across diagnostic boundaries, we are opening new pathways to understand and treat suffering that affects so many. This award strengthens the vital ties between UK and French research communities, fostering an environment ripe for groundbreaking discoveries."

Professor Marion Leboyer, CEO of Fondation FondaMental, articulated the profound significance of the initiative: "For too long, mental health diagnostics have relied on a subjective framework, leading to delayed interventions and often inadequate treatments. The Precision Mind Award, born from our Franco-British consortium, represents a bold step towards a future of precision psychiatry. Inspired by the successes in neurodegenerative diseases, we are confident that by identifying objective biomarkers, we can revolutionize patient care, offering more accurate diagnoses and truly personalized therapies. The two laureate projects tackle incredibly challenging areas, and their success will bring immense hope to patients and families."

The laureate principal investigators also expressed their gratitude and excitement. Dr. Adam Al-Diwani from the University of Oxford commented, "Receiving the Precision Mind Award for AUTOSCREEN is a tremendous validation of our work. The support from Wakam and the consortium will allow us to accelerate our research into autoimmune psychoses, bringing us closer to a future where these often-misunderstood conditions can be identified earlier and treated with targeted, effective immunological interventions. The collaborative aspect with Dr. Groc’s team is invaluable." Dr. Laurent Groc from the University of Bordeaux added, "This award is a fantastic opportunity to deepen our understanding of the nanoscale mechanisms behind autoimmune psychoses. The synergy between our labs, combining advanced imaging with cutting-edge cellular models, is key to unlocking new diagnostic and therapeutic avenues. We are immensely grateful for this recognition and support."

Dr. Mireille Laforge from INSERM in Paris stated, "Anhedonia is a profoundly disabling symptom that impacts the lives of countless patients. The NIHR’s support for our Immuno-Metabolic Profile project is crucial for unraveling its complex biological roots. Our collaboration with Dr. Corsi-Zuelli’s team in Oxford, integrating diverse expertise and leveraging advanced platforms, will allow us to move closer to developing personalized treatments for this challenging aspect of mental illness." Dr. Fabiana Corsi-Zuelli from the University of Oxford concluded, "We are thrilled to be recognized by the Precision Mind Award. This funding will enable us to explore the intricate links between inflammation, metabolism, and anhedonia, which holds immense promise for developing novel therapeutic targets. Working closely with Dr. Laforge’s team in Paris and utilizing the UK Mental Health Platform exemplifies the power of international scientific collaboration in tackling complex, global health challenges."

Broader Impact and Implications: A New Era for Mental Health

The Precision Mind Award and the underlying Franco-British consortium represent far more than just a funding mechanism; they signify a paradigm shift in how mental illness is approached. The broader implications are profound and multifaceted:

• Revolutionizing Diagnosis and Treatment: The successful identification and validation of biomarkers could transform psychiatry from a largely descriptive and symptom-based field to one grounded in objective, biological evidence. This would enable earlier, more accurate diagnoses, allowing for timely intervention before conditions become entrenched. It would also facilitate the development of personalized medicine approaches, where treatments are selected based on a patient’s unique biological profile, moving away from the current trial-and-error model that can prolong suffering and delay recovery.
• Reducing Stigma: A biological understanding of mental illness, supported by objective markers, can help to destigmatize these conditions. By demonstrating that mental illnesses have tangible biological underpinnings, similar to physical diseases, it can foster greater empathy and understanding, encouraging more people to seek help without fear of judgment.
• Accelerating Drug Discovery: Biomarkers provide critical tools for drug development. They can identify patient subgroups most likely to respond to specific treatments, serve as objective endpoints in clinical trials, and help monitor treatment efficacy, thereby accelerating the discovery and approval of novel, more effective psychiatric medications.
• Fostering International Collaboration: The Precision Mind Award stands as a shining example of the power of international collaboration in tackling global health challenges. Complex problems like mental illness require diverse perspectives, shared resources, and synergistic expertise across national borders. The success of this Franco-British consortium can serve as a model for future partnerships in other critical areas of medical research.
• Public-Private Partnerships: Wakam’s involvement highlights the growing recognition within the private sector of its role in advancing public health. Such public-private partnerships are crucial for bringing together financial resources, innovative thinking, and scientific expertise to address complex societal needs that traditional funding mechanisms alone might struggle to fully support.
• Economic and Social Benefits: Improved mental health outcomes translate directly into significant economic and social benefits. A healthier population is a more productive population, leading to reduced healthcare costs, decreased disability, and a stronger social fabric. The investments made today in biomarker research promise substantial returns in human well-being and societal resilience.
• Ethical Considerations: As biomarker research advances, it will be crucial to address ethical considerations, including data privacy, potential implications for genetic information, and equitable access to new diagnostic and treatment modalities. The consortium’s commitment to independent scientific review suggests a foundation for responsible research practices.

The unveiling of the Precision Mind Award laureates marks a new dawn for mental health research. The selected projects, backed by a powerful Franco-British consortium and dedicated partners, are poised to unravel the intricate biological mysteries of mental illness. By pushing the boundaries of scientific discovery, the Precision Mind Award is not just recognizing excellence but actively catalyzing a future where mental health care is precise, personalized, and profoundly transformative for the one billion people affected by these conditions worldwide.